ArticleBioinformatics (Oxford, England)2024
DeepRSMA: a cross-fusion-based deep learning method for RNA-small molecule binding affinity prediction.
Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- In silico designing of small molecules for targeting RNA: current landscape and future directions.Journal of computer-aided molecular design · 2026Review
- Accurate RNA-Ligand Binding Site Prediction Based on a Multi-Channel Graph Neural Network.Interdisciplinary sciences, computational life sciences · 2026Article
- Mammalian therapeutic riboswitches: Engineering and custom ligands.Molecular therapy. Nucleic acids · 2026Review
- DLRNA-BERTa: a transformer approach for predicting molecule-RNA binding affinities.Briefings in bioinformatics · 2026Article
- Machine Learning for RNA-Targeting Drug Design.Journal of chemical information and modeling · 2026Review
- DeepLMI: deep feature mining with a globally enhanced graph convolutional network for robust lncRNA-miRNA interaction prediction.Bioinformatics (Oxford, England) · 2026Article
- Advances in computational prediction of RNA-small molecule binding affinity.Journal of computer-aided molecular design · 2026Review
- DeepRNA-DTI: a deep learning approach for RNA-compound interaction prediction with binding site interpretability.Journal of cheminformatics · 2025Article
- Beyond the niche - unlocking the full potential of synthetic riboswitches.Nature communications · 2025Review
- MVRBind: multi-view learning for RNA-small molecule binding site prediction.Briefings in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
motivationRNA is implicated in numerous aberrant cellular functions and disease progressions, highlighting the crucial importance of RNA-targeted drugs. To accelerate the discovery of such drugs, it is essential to develop an effective computational method for predicting RNA-small molecule affinity (RSMA). Recently, deep learning-based computational methods have been promising due to their powerful nonlinear modeling ability. However, the leveraging of advanced deep learning methods to mine the diverse information of RNAs, small molecules, and their interaction still remains a great challenge.
resultsIn this study, we present DeepRSMA, an innovative cross-attention-based deep learning method for RSMA prediction. To effectively capture fine-grained features from RNA and small molecules, we developed nucleotide-level and atomic-level feature extraction modules for RNA and small molecules, respectively. Additionally, we incorporated both sequence and graph views into these modules to capture features from multiple perspectives. Moreover, a transformer-based cross-fusion module is introduced to learn the general patterns of interactions between RNAs and small molecules. To achieve effective RSMA prediction, we integrated the RNA and small molecule representations from the feature extraction and cross-fusion modules. Our results show that DeepRSMA outperforms baseline methods in multiple test settings. The interpretability analysis and the case study on spinal muscular atrophy demonstrate that DeepRSMA has the potential to guide RNA-targeted drug design. AVAILABILITY AND IMPLEMENTATION: The codes and data are publicly available at https://github.com/Hhhzj-7/DeepRSMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.